7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline

Identification

Name
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline
Accession Number
DB08550
Type
Small Molecule
Groups
Experimental
Description

Potent reversible inhibitor of phenylethanolamine N-methyltransferase.

Structure
Thumb
Synonyms
Not Available
External IDs
SKF-64139 FREE BASE
Categories
UNII
A0EP5O913J
CAS number
61563-24-4
Weight
Average: 202.08
Monoisotopic: 201.011204707
Chemical Formula
C9H9Cl2N
InChI Key
WFPUBEDBBOGGIQ-UHFFFAOYSA-N
InChI
InChI=1S/C9H9Cl2N/c10-8-2-1-6-3-4-12-5-7(6)9(8)11/h1-2,12H,3-5H2
IUPAC Name
7,8-dichloro-1,2,3,4-tetrahydroisoquinoline
SMILES
ClC1=CC=C2CCNCC2=C1Cl

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UPhenylethanolamine N-methyltransferaseNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-Methylenedioxyamphetamine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
Acarbose7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Acarbose.Approved, Investigational
Acebutolol7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Acebutolol.Approved
AlaproclateThe risk or severity of adverse effects can be increased when Alaproclate is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
Albiglutide7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Albiglutide.Approved
AlfentanilAlfentanil may increase the serotonergic activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved, Illicit
Aliskiren7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved, Investigational
Alogliptin7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Alogliptin.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Illicit
Alprenolol7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved
Ambrisentan7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Amineptine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Amineptine.Illicit, Withdrawn
Amitriptyline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Amitriptyline.Approved
Amlodipine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Amlodipine.Approved
AmoxapineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Amoxapine.Approved
Amphetamine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Amphetamine.Approved, Illicit
ApomorphineThe metabolism of Apomorphine can be decreased when combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Apraclonidine.Approved
ArbutamineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Arformoterol.Approved, Investigational
Atenolol7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Atenolol.Approved
Atomoxetine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the central neurotoxic activities of Atomoxetine.Approved
Atropine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Atropine.Approved, Vet Approved
BambuterolThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Bambuterol.Approved
Benazepril7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Benazepril.Approved, Investigational
Bendroflumethiazide7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Bendroflumethiazide.Approved
Benmoxin7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Benmoxin.Withdrawn
Benzphetamine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Benzphetamine.Approved, Illicit
Bepridil7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetahistineThe serum concentration of Betahistine can be increased when it is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved
Betaxolol7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Betaxolol.Approved
Bethanidine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Bethanidine.Approved
BezafibrateThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Bezafibrate.Approved
Bietaserpine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Bietaserpine.Experimental
Bimatoprost7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Bimatoprost.Approved, Investigational
Bisoprolol7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Bisoprolol.Approved
Bosentan7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Bosentan.Approved, Investigational
BQ-1237,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of BQ-123.Investigational
Bretylium7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Brimonidine.Approved
Brofaromine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Brofaromine.Experimental
Bromocriptine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
Bupranolol7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved, Illicit, Investigational, Vet Approved
Bupropion7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved, Investigational
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved, Illicit, Vet Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved
Cadralazine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Cadralazine.Experimental
Cafedrine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Cafedrine.Investigational
Canagliflozin7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Canagliflozin.Approved
Candesartan7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Candesartan.Approved
Candoxatril7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Candoxatril.Experimental
Captopril7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Illicit, Vet Approved
Caroxazone7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Caroxazone.Withdrawn
Carteolol7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Carteolol.Approved
Carvedilol7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Carvedilol.Approved, Investigational
Celiprolol7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Celiprolol.Approved, Investigational
Chlorothiazide7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
Chlorphentermine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Chlorphentermine.Illicit, Withdrawn
Chlorpropamide7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Chlorpropamide.Approved
Chlorthalidone7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Chlorthalidone.Approved
Cicletanine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Cicletanine.Investigational
Cilazapril7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Cilazapril.Approved
Cirazoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Cirazoline.Experimental
Citalopram7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Citalopram.Approved
Clemastine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the anticholinergic activities of Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Clenbuterol.Approved, Vet Approved
Clomipramine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Clomipramine.Approved, Vet Approved
Clonidine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Clonidine.Approved
Cloranolol7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Cloranolol.Experimental
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved, Illicit
Cryptenamine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Cryptenamine.Approved
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved
Cyclopenthiazide7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Cyclopenthiazide.Experimental
Cyclothiazide7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Cyclothiazide.Approved
Cyproheptadine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the anticholinergic activities of Cyproheptadine.Approved
Dapagliflozin7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Dapagliflozin.Approved
Dapoxetine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Dapoxetine.Investigational
Debrisoquin7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Debrisoquin.Approved
Delapril7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Delapril.Experimental
Deserpidine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Deserpidine.Approved
Desipramine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Desipramine.Approved
Desvenlafaxine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Desvenlafaxine.Approved
Dexmethylphenidate7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Dexmethylphenidate.Approved
Dextroamphetamine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Dextroamphetamine.Approved, Illicit
Dextromethorphan7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved
Diazoxide7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Diazoxide.Approved
Dibenzepin7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Dibenzepin.Experimental
diethylnorspermine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of diethylnorspermine.Investigational
Diethylpropion7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Diethylpropion.Approved, Illicit
Dihydralazine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Dihydralazine.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved, Illicit
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental, Illicit
Diltiazem7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Diltiazem.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved, Illicit
DipivefrinThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Dipivefrin.Approved
Disopyramide7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Disopyramide.Approved
DobutamineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Dobutamine.Approved
DomperidoneThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Domperidone.Approved, Investigational, Vet Approved
Dorzolamide7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Dorzolamide.Approved
Dosulepin7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Dosulepin.Approved
Doxapram7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Doxapram.Approved, Vet Approved
Doxazosin7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Doxazosin.Approved
Doxepin7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Doxepin.Approved
Doxylamine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the anticholinergic activities of Doxylamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Investigational
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental, Illicit
DroxidopaThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Droxidopa.Approved, Investigational
Dulaglutide7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Dulaglutide.Approved
Duloxetine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Duloxetine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental, Illicit
Efonidipine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe metabolism of Eletriptan can be decreased when combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved, Investigational
Empagliflozin7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Empagliflozin.Approved
Enalapril7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Enalapril.Approved, Vet Approved
Enalaprilat7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Enalaprilat.Approved
Endralazine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Endralazine.Experimental
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved, Investigational
Epanolol7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Epanolol.Experimental
EphedraThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Ephedra.Approved, Nutraceutical, Withdrawn
Epoprostenol7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Epoprostenol.Approved
Eprosartan7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Eprosartan.Approved
Ergotamine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Ergotamine.Approved
Escitalopram7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Escitalopram.Approved, Investigational
Esmirtazapine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Esmirtazapine.Investigational
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved, Illicit
Etoperidone7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Illicit, Vet Approved
Exenatide7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Exenatide.Approved, Investigational
Felodipine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Felodipine.Approved, Investigational
FenfluramineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Fenfluramine.Illicit, Withdrawn
Fenoldopam7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Fenoldopam.Approved
FenoterolThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Fenoterol.Approved
FentanylFentanyl may increase the serotonergic activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved, Illicit, Investigational, Vet Approved
Ferulic acid7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Ferulic acid.Experimental
Fluoxetine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
Fluvoxamine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Fluvoxamine.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Formoterol.Approved, Investigational
Fosinopril7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Fosinopril.Approved
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved, Investigational
FurazolidoneFurazolidone may increase the hypertensive activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved, Vet Approved
GepefrineThe risk or severity of adverse effects can be increased when Gepefrine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
Gliclazide7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Gliclazide.Approved
Glimepiride7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Glimepiride.Approved
Glipizide7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Glipizide.Approved
Glyburide7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Glyburide.Approved
Guanabenz7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Guanabenz.Approved
Guanadrel7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Guanadrel.Approved
Guanazodine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Guanazodine.Experimental
Guanethidine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Guanethidine.Approved
Guanfacine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Guanfacine.Approved, Investigational
Guanoclor7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Guanoclor.Experimental
Guanoxabenz7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Guanoxabenz.Experimental
Guanoxan7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Guanoxan.Experimental
Harmaline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Harmaline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved, Illicit
Hexamethonium7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Hexamethonium.Experimental
Hydracarbazine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Hydracarbazine.Experimental
Hydralazine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Hydralazine.Approved
Hydrochlorothiazide7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Hydrocodone.Approved, Illicit
Hydroflumethiazide7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Hydromorphone.Approved, Illicit
Hydroxyamphetamine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Hydroxyamphetamine.Approved
Imidapril7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Imidapril.Investigational
Imipramine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Imipramine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Indacaterol.Approved
Indalpine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
Indapamide7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Indapamide.Approved
Indenolol7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Indenolol.Withdrawn
Indoramin7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Indoramin.Withdrawn
Insulin Aspart7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin Detemir7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin Glargine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin Glulisine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin Human7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin Lispro7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Insulin Lispro.Approved
Iofetamine I-123The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved
Iprindole7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Iprindole.Experimental
Iproclozide7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Iproclozide.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Withdrawn
Irbesartan7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypertensive activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved
IsoetarineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Isoetarine.Approved
IsomethepteneThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Isometheptene.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Isoprenaline.Approved
Isradipine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Isradipine.Approved
Ketanserin7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Ketanserin.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved, Nutraceutical, Withdrawn
Labetalol7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Labetalol.Approved
Lacidipine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Lacidipine.Approved
Latanoprost7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Latanoprost.Approved, Investigational
Lercanidipine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved
Levomilnacipran7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Levomilnacipran.Approved
Levonordefrin7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Levonordefrin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Levosalbutamol.Approved
LinezolidThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Linezolid.Approved, Investigational
Linsidomine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Linsidomine.Experimental
Liraglutide7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Liraglutide.Approved
Lisdexamfetamine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Lisdexamfetamine.Approved, Investigational
Lisinopril7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved
LithiumThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Illicit
Lofepramine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Lofepramine.Experimental
Lofexidine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Lofexidine.Approved, Investigational
Losartan7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Losartan.Approved
Macitentan7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Macitentan.Approved
Manidipine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Manidipine.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved
Mebanazine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Mebanazine.Withdrawn
Mecamylamine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Mecamylamine.Approved
Mecasermin7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Mephedrone7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Mephedrone.Investigational
Mephentermine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Mephentermine.Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
Mequitazine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the anticholinergic activities of Mequitazine.Approved
Metaraminol7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Metaraminol.Approved, Investigational
Metformin7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved, Illicit
Methamphetamine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Methamphetamine.Approved, Illicit
Methoserpidine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Methoserpidine.Experimental
Methoxamine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Methoxamine.Approved
MethoxyphenamineThe risk or severity of adverse effects can be increased when Methoxyphenamine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
MethyldopaThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
Methylene blue7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Methylene blue.Investigational
Methylphenidate7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Methylphenidate.Approved, Investigational
Metipranolol7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Metipranolol.Approved
Metolazone7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Metolazone.Approved
Metoprolol7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Metoprolol.Approved, Investigational
Metyrosine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Metyrosine.Approved
Mianserin7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the neurotoxic activities of Mianserin.Approved
Mibefradil7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Mibefradil.Withdrawn
Midodrine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Midodrine.Approved
Midomafetamine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
Mifepristone7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
Miglitol7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Miglitol.Approved
Milnacipran7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Milnacipran.Approved
MinaprineMinaprine may increase the hypertensive activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved
Minoxidil7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Minoxidil.Approved
Mirtazapine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the central neurotoxic activities of Mirtazapine.Approved
MMDA7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Moclobemide.Approved
Moexipril7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Moexipril.Approved
Moxonidine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Moxonidine.Approved
Muzolimine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Muzolimine.Experimental
Nadolol7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Nadolol.Approved
Naftopidil7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved
NaratriptanThe metabolism of Naratriptan can be decreased when combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved, Investigational
Nateglinide7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
Nebivolol7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Nebivolol.Approved, Investigational
Nefazodone7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NialamideNialamide may increase the hypertensive activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Withdrawn
Nicardipine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Nicardipine.Approved
Nicorandil7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Nicorandil.Approved
Niguldipine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Niguldipine.Experimental
Nilvadipine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Nilvadipine.Approved
Nimodipine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Nimodipine.Approved
Nisoldipine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Nisoldipine.Approved
Nitrendipine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Nitrendipine.Approved
Nitroprusside7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Nitroprusside.Approved
Norepinephrine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Norepinephrine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved, Illicit
Nortriptyline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Nortriptyline.Approved
Octamoxin7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Olanzapine.Approved, Investigational
Olmesartan7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Olodaterol.Approved
Omapatrilat7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Omapatrilat.Investigational
Opipramol7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Orciprenaline.Approved
Oxprenolol7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Oxprenolol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved, Investigational, Vet Approved
Pargyline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Pargyline.Approved
Paroxetine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Paroxetine.Approved, Investigational
Penbutolol7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Penbutolol.Approved, Investigational
Pentamidine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved, Vet Approved
Pentolinium7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Pentolinium.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved, Vet Approved, Withdrawn
Perindopril7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Perindopril.Approved
Pethidine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
PhenelzinePhenelzine may increase the hypertensive activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved
Pheniprazine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Pheniprazine.Withdrawn
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
Phenoxybenzamine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Phenoxybenzamine.Approved
Phenoxypropazine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Phenoxypropazine.Withdrawn
Phentermine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Phentermine.Approved, Illicit
Phentolamine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Phentolamine.Approved
Phenylephrine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PholcodinePholcodine may increase the serotonergic activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved, Illicit
PiclozotanThe metabolism of Piclozotan can be decreased when combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Investigational
Pinacidil7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Pinacidil.Withdrawn
Pindolol7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Pindolol.Approved
Pioglitazone7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Investigational
PirlindolePirlindole may increase the hypertensive activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved
Pivhydrazine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Pivhydrazine.Withdrawn
Pizotifen7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the anticholinergic activities of Pizotifen.Approved
Polythiazide7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Polythiazide.Approved
Pramlintide7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
Prazosin7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Prazosin.Approved
ProcaterolThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Procaterol.Approved
Propranolol7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Propranolol.Approved, Investigational
Protriptyline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Protriptyline.Approved
PRX-00023The metabolism of PRX-00023 can be decreased when combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Investigational
Pseudoephedrine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Pseudoephedrine.Approved
Quinapril7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Quinapril.Approved, Investigational
Quinine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Quinine.Approved
Ramipril7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Ramipril.Approved
RasagilineRasagiline may increase the hypertensive activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved
RemifentanilRemifentanil may increase the serotonergic activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved
Remikiren7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Remikiren.Approved
Repaglinide7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
Rescinnamine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Reserpine.Approved
Rilmenidine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Rilmenidine.Investigational
Riociguat7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Riociguat.Approved
Ritobegron7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Ritodrine.Approved
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved
RopiniroleThe metabolism of Ropinirole can be decreased when combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved, Investigational
Rosiglitazone7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
Safrazine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Safrazine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Salmeterol.Approved
Saprisartan7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Saprisartan.Experimental
Saxagliptin7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Saxagliptin.Approved
SelegilineSelegiline may increase the hypertensive activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved, Investigational, Vet Approved
Selexipag7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Selexipag.Approved
Sertraline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Sertraline.Approved
Sitagliptin7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
Sitaxentan7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Spirapril7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Spirapril.Approved
SufentanilSufentanil may increase the serotonergic activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved, Investigational
Sulfadiazine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
Sulfamethoxazole7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Sulfamethoxazole.Approved
Sulfisoxazole7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SumatriptanThe metabolism of Sumatriptan can be decreased when combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved, Investigational
Sunitinib7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
Talinolol7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Talinolol.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved
Telmisartan7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Telmisartan.Approved, Investigational
Temocapril7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerbutalineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Terbutaline.Approved
Terlipressin7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Terlipressin.Approved, Investigational
Testosterone PropionateThe risk or severity of adverse effects can be increased when Testosterone Propionate is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved
Tetrahydropalmatine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Tetrahydropalmatine.Investigational
Tetryzoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Tetryzoline.Approved
Theodrenaline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Theodrenaline.Investigational
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved
Tibolone7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Tibolone.Approved
Ticrynafen7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Ticrynafen.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
Timolol7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Timolol.Approved
Tolazamide7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Tolazamide.Approved
Tolazoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
Tolbutamide7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved, Withdrawn
Tolonidine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypertensive activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved
Torasemide7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Torasemide.Approved
TramadolTramadol may increase the neuroexcitatory activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved, Investigational
Trandolapril7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Trandolapril.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
TranylcypromineTranylcypromine may increase the hypertensive activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved
Travoprost7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Travoprost.Approved
TrazodoneThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Trazodone.Approved, Investigational
Treprostinil7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Treprostinil.Approved, Investigational
Trichlormethiazide7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
Trimazosin7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Trimazosin.Experimental
Trimethaphan7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Trimethaphan.Approved
Trimipramine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Trimipramine.Approved
Unoprostone7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Unoprostone.Approved
Urapidil7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Urapidil.Investigational
Valsartan7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Valsartan.Approved, Investigational
Venlafaxine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Venlafaxine.Approved
VilanterolThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Vilanterol.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved
Vincamine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Vincamine.Experimental
Vinpocetine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Vinpocetine.Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved
Xipamide7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Xipamide.Experimental
Xylometazoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Xylometazoline.Approved
Zimelidine7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Zimelidine.Withdrawn
Zofenopril7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Zofenopril.Experimental
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Kenneth G. Holden, Carl D. Perchonock, "Method for preparing 7,8-dichloro-1,2,3,4-tetrahydroisoquinoline." U.S. Patent US4200754, issued February, 1976.

US4200754
General References
Not Available
External Links
PubChem Compound
123920
PubChem Substance
99445021
ChemSpider
110451
BindingDB
13014
ChEBI
160129
ChEMBL
CHEMBL287837
HET
SKA
ATC Codes
Not Available
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.139 mg/mLALOGPS
logP2.68ALOGPS
logP2.78ChemAxon
logS-3.2ALOGPS
pKa (Strongest Basic)8.35ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area12.03 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity52.23 m3·mol-1ChemAxon
Polarizability19.82 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9946
Blood Brain Barrier+0.9774
Caco-2 permeable+0.6236
P-glycoprotein substrateSubstrate0.7056
P-glycoprotein inhibitor INon-inhibitor0.6028
P-glycoprotein inhibitor IINon-inhibitor0.879
Renal organic cation transporterInhibitor0.6923
CYP450 2C9 substrateNon-substrate0.8528
CYP450 2D6 substrateNon-substrate0.6446
CYP450 3A4 substrateNon-substrate0.6057
CYP450 1A2 substrateInhibitor0.7823
CYP450 2C9 inhibitorNon-inhibitor0.7498
CYP450 2D6 inhibitorInhibitor0.7316
CYP450 2C19 inhibitorNon-inhibitor0.6595
CYP450 3A4 inhibitorNon-inhibitor0.7796
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5249
Ames testNon AMES toxic0.7517
CarcinogenicityNon-carcinogens0.9147
BiodegradationNot ready biodegradable0.9727
Rat acute toxicity2.9080 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6871
hERG inhibition (predictor II)Inhibitor0.6952
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as tetrahydroisoquinolines. These are tetrahydrogenated isoquinoline derivatives.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Tetrahydroisoquinolines
Sub Class
Not Available
Direct Parent
Tetrahydroisoquinolines
Alternative Parents
Aralkylamines / Benzenoids / Aryl chlorides / Dialkylamines / Azacyclic compounds / Organopnictogen compounds / Organochlorides / Hydrocarbon derivatives
Substituents
Tetrahydroisoquinoline / Aralkylamine / Aryl chloride / Aryl halide / Benzenoid / Secondary aliphatic amine / Secondary amine / Azacycle / Organonitrogen compound / Organochloride
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organochlorine compound, isoquinolines (CHEBI:160129)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Phenylethanolamine n-methyltransferase activity
Specific Function
Converts noradrenaline to adrenaline.
Gene Name
PNMT
Uniprot ID
P11086
Uniprot Name
Phenylethanolamine N-methyltransferase
Molecular Weight
30854.745 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on September 15, 2010 15:32 / Updated on October 02, 2017 06:07